Compounded semaglutide and brand-name Wegovy both contain the active ingredient semaglutide, a GLP-1 receptor agonist approved for weight management and glucose control. The key distinction lies in manufacturing and regulatory oversight. Wegovy is produced under FDA approval with standardized manufacturing processes, quality control protocols, and pharmacokinetic validation. Compounded semaglutide is prepared by state-licensed pharmacies under the authority of the Pharmacy Compounding Accreditation Board (PCAB) or similar oversight, with formulations that may vary by compounding pharmacy. Both forms deliver semaglutide through subcutaneous injection at equivalent dosing intervals, though bioavailability and consistency may differ between compounded preparations and the branded product due to variations in excipient composition and manufacturing precision.
The primary clinical consideration for prescribers involves access and cost efficiency balanced against quality assurance certainty. Compounded semaglutide typically costs 40 to 60 percent less than Wegovy, with prices ranging from approximately 150 to 250 dollars per month depending on the compounding pharmacy, whereas Wegovy costs 900 to 1300 dollars monthly without insurance coverage. This cost differential significantly impacts patient access and adherence, particularly for individuals without insurance or with high deductible plans. However, prescribers should counsel patients that compounded preparations lack the extensive clinical trial data and manufacturing standardization inherent to FDA-approved Wegovy. Documentation of pharmacy accreditation and quality assurance practices is advisable when recommending compounded formulations.
Safety profiles remain comparable when compounded semaglutide is sourced from accredited pharmacies, with reported adverse events and contraindications paralleling those of brand-name Wegovy, including gastrointestinal side effects, pancreatitis risk, and contraindication in patients with personal or family history of medullary thyroid carcinoma. Prescribers should verify that the compounding pharmacy maintains PCAB accreditation or equivalent oversight, confirm appropriate patient screening for contraindications regardless of formulation source, and monitor patients on compounded semaglutide with the same clinical vigilance applied to branded therapy.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
What is the difference between compounded semaglutide and Wegovy?
Wegovy is the FDA-approved brand-name version of semaglutide made by Novo Nordisk in regulated manufacturing facilities. Compounded semaglutide is a custom-made version prepared by pharmacies under different regulatory standards, which may vary in quality and consistency.
Is compounded semaglutide as safe as Wegovy?
Wegovy has undergone rigorous FDA testing and manufacturing oversight, whereas compounded semaglutide is made under less stringent quality control standards. This means compounded versions carry higher risks for contamination, inconsistent dosing, or impurities.
Why would someone choose compounded semaglutide over Wegovy?
The main reason is cost. Compounded semaglutide is typically much cheaper than Wegovy because it avoids the research and development expenses that brand-name drugs include. Some patients also choose it for faster access when Wegovy has supply limitations.
Does insurance cover compounded semaglutide the same way it covers Wegovy?
No. Insurance companies are more likely to cover FDA-approved Wegovy through standard prescription coverage, while compounded semaglutide coverage varies widely depending on your specific plan. Many insurance plans do not cover compounded medications at all.
Can my doctor prescribe compounded semaglutide legally?
Yes, doctors can legally prescribe compounded semaglutide under US pharmacy compounding laws. However, your doctor may have concerns about safety and consistency, so discuss this directly with them before requesting a compounded version.
What quality control issues should I know about with compounded semaglutide?
Compounded pharmacies are not required to meet the same manufacturing standards as FDA-approved manufacturers, which means the actual dose in each injection may vary. Contamination or chemical degradation is also a greater risk compared to Wegovy.
How much does compounded semaglutide cost compared to Wegovy?
Compounded semaglutide typically costs 50 to 70 percent less than Wegovy, though prices vary by pharmacy and location. Wegovy costs several hundred dollars per month without insurance, while compounded versions may range from $100 to $300 per month.
If I start with compounded semaglutide, can I switch to Wegovy later?
Yes, you can switch between them, but your doctor may need to adjust your dosing schedule since the two products may differ in consistency and potency. Talk to your doctor about the best way to transition safely.
Are there any compounded semaglutide options that are safer than others?
Compounded pharmacies that are State Board of Pharmacy licensed and have additional accreditations offer slightly more assurance, but they still lack the FDA oversight that Wegovy has. Always ask your pharmacy about their quality control processes and certifications.
What should I do if I’m concerned about the safety of compounded semaglutide?
Discuss your concerns with your prescribing physician, who can help you weigh the cost savings against safety risks based on your individual health needs. Your doctor may recommend sticking with Wegovy, seeking insurance coverage assistance, or exploring other weight loss treatments instead.
